Literature DB >> 1532629

Aspirin: dose and indications in modern stroke prevention.

J van Gijn1.   

Abstract

Until recently, a gap existed between the rapidly advancing knowledge about the pharmacology of aspirin and the management of patients who are threatened by stroke. In doses as low as 20 to 40 mg per day, aspirin can completely suppress the production of the aggregant agent thromboxane A2. The clinical evidence, however, which shows a reduction of 20% to 25% in the incidence of vascular death, stroke, or myocardial infarction, is based on trials with 300 to 1300 mg of aspirin per day. The clinicians are catching up now that recent trials have demonstrated similar effects with 30 or 75 mg of aspirin per day, and with fewer side effects. The hope that the protective effects of these low doses would be even greater, thanks to the sparing of the prostaglandin synthesis in endothelial tissue, has not yet materialized.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532629

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  4 in total

1.  Comparative pharmacokinetics of Aspegic 1000 mg i.v. versus 1000 mg i.m. thrice daily.

Authors:  B Nia; J M Vergnaud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

Review 2.  Oral antiplatelet therapy for acute ischaemic stroke.

Authors:  Jatinder S Minhas; Tamara Chithiramohan; Xia Wang; Sam C Barnes; Rebecca H Clough; Meeriam Kadicheeni; Lucy C Beishon; Thompson Robinson
Journal:  Cochrane Database Syst Rev       Date:  2022-01-14

Review 3.  Oral antiplatelet therapy for acute ischaemic stroke.

Authors:  Peter A G Sandercock; Carl Counsell; Mei-Chiun Tseng; Emanuela Cecconi
Journal:  Cochrane Database Syst Rev       Date:  2014-03-26

4.  Aspirin promotes oligodendrocyte precursor cell proliferation and differentiation after white matter lesion.

Authors:  Jing Chen; Shilun Zuo; Jing Wang; Jian Huang; Xiao Zhang; Yang Liu; Yunxia Zhang; Jun Zhao; Junliang Han; Lize Xiong; Ming Shi; Zhirong Liu
Journal:  Front Aging Neurosci       Date:  2014-01-27       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.